[Test Bank for Edmunds’ Pharmacology for the
Primary Care Provider, 5th Edition] EXAM with
Questions and Answers/Plus a Rationale Updated
2026 A+/Instant Download PDF
EXAM COVERAGE
1. Principles of Pharmacokinetics and Pharmacodynamics
2. Pharmacology of the Autonomic Nervous System
3. Cardiovascular and Antihypertensive Agents
4. Respiratory System Pharmacology
5. Endocrine and Metabolic Agents
6. Gastrointestinal and Renal Pharmacology
7. Psychopharmacology and Neurological Agents
8. Anti-infective and Antimicrobial Therapy
9. Pain Management and Analgesics
10. Evidence-Based Prescribing and Clinical Decision Making
1. A 68-year-old patient with chronic heart failure and renal insufficiency presents for a medication
review. The patient is currently taking lisinopril, furosemide, and spironolactone. Laboratory
results show a serum potassium of 5.6 mEq/L and a creatinine clearance of 35 mL/min. Which
action is the most appropriate management strategy?
A. Continue all medications as prescribed and recheck potassium in 2 weeks.
, B. Discontinue the spironolactone and monitor potassium levels closely.
C. Increase the dose of lisinopril to improve cardiac output.
D. Switch the patient to a thiazide diuretic for better potassium balance.
Answer: B
Rationale: Spironolactone is a potassium-sparing diuretic that carries a high risk of
hyperkalemia, particularly in patients with renal impairment or those taking ACE inhibitors like
lisinopril. Discontinuing the spironolactone is the safest immediate action to address the
hyperkalemia (5.6 mEq/L). Increasing lisinopril or switching to another diuretic does not resolve
the current electrolyte toxicity.
CORRECT ANSWER : B
2. A patient with type 2 diabetes and stable coronary artery disease is being evaluated for glycemic
control. The patient has a history of heart failure with reduced ejection fraction. Which class of
antidiabetic agents should be prioritized for this patient due to its proven cardiovascular
mortality benefits?
A. Sulfonylureas (e.g., glipizide)
B. Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin)
C. Sodium-glucose cotransporter-2 (SGLT2) inhibitors (e.g., empagliflozin)
D. Thiazolidinediones (e.g., pioglitazone)
Answer: C
Rationale: SGLT2 inhibitors have established clinical evidence for reducing cardiovascular
death and hospitalizations in patients with heart failure and T2DM. DPP-4 inhibitors are neutral
regarding heart failure, sulfonylureas have a risk of hypoglycemia, and thiazolidinediones are
generally contraindicated in heart failure due to fluid retention.
CORRECT ANSWER : C
3. A 45-year-old female presents with primary hypothyroidism. She is currently stable on 112 mcg
of levothyroxine daily. She is now requesting a prescription for a combined oral contraceptive.
What is the most important clinical consideration when starting this therapy?
A. The estrogen in the contraceptive increases thyroid-binding globulin, requiring a potential
increase in levothyroxine dose.
B. The contraceptive will decrease the absorption of levothyroxine in the gut.
, C. The contraceptive must be taken at least 6 hours apart from the thyroid medication.
D. The patient will likely require a switch to liothyronine (T3) for stability.
Answer: A
Rationale: Estrogen increases the levels of thyroid-binding globulin, which binds to thyroid
hormone and reduces the amount of free hormone available, necessitating a dose increase of
levothyroxine. Absorption interference (Option B) is not the primary mechanism, and T3 (Option
D) is not indicated for stability.
CORRECT ANSWER : A
4. A patient has been prescribed a non-selective beta-blocker for migraine prophylaxis. During the
assessment, the patient mentions a history of asthma. Which clinical concern is most urgent?
A. The beta-blocker may cause excessive bradycardia in asthma patients.
B. Non-selective beta-blockers can cause bronchoconstriction by blocking beta-2 receptors in the
lungs.
C. The patient will experience a significant increase in their albuterol requirements.
D. Asthma medications will render the beta-blocker completely ineffective.
Answer: B
Rationale: Non-selective beta-blockers antagonize both beta-1 (cardiac) and beta-2 (bronchial)
receptors, which can precipitate bronchospasm in patients with reactive airway disease. This is
a classic pharmacological contraindication that necessitates caution or selection of a
cardioselective beta-1 antagonist.
CORRECT ANSWER : B
5. A patient with severe seasonal allergies is taking fexofenadine but reports inadequate control of
nasal congestion. Which pharmacological intervention is the best evidence-based step?
A. Add an oral pseudoephedrine for long-term use.
B. Transition the patient to an intranasal corticosteroid (e.g., fluticasone).
C. Increase the dose of fexofenadine to twice the standard daily dose.
D. Add a first-generation antihistamine like diphenhydramine to the regimen.
Answer: B
, Rationale: Intranasal corticosteroids are the most effective monotherapy for allergic rhinitis,
particularly for congestion. Pseudoephedrine has cardiovascular risks with long-term use,
higher antihistamine doses offer little additional benefit for congestion, and first-generation
antihistamines cause sedation.
CORRECT ANSWER : B
6. A patient is taking warfarin for atrial fibrillation. The patient is diagnosed with a urinary tract
infection and is prescribed sulfamethoxazole-trimethoprim (Bactrim). What is the primary drug-
drug interaction mechanism?
A. Bactrim increases the metabolism of warfarin, decreasing its effect.
B. Bactrim inhibits CYP2C9, significantly increasing the INR and bleeding risk.
C. The patient will experience a synergistic decrease in blood pressure.
D. Bactrim binds to warfarin in the GI tract, preventing absorption.
Answer: B
Rationale: Sulfamethoxazole-trimethoprim is a potent inhibitor of CYP2C9, the enzyme
responsible for the metabolism of the S-enantiomer of warfarin. This interaction dramatically
increases warfarin levels and bleeding risk, requiring preemptive dose reductions or close
monitoring.
CORRECT ANSWER : B
7. A patient with stable depression is treated with fluoxetine (SSRI). The patient requests a
prescription for dextromethorphan for a cough. What is the potential risk of this combination?
A. Reduced antitussive effect.
B. Serotonin syndrome.
C. Potentiation of sedation.
D. Acute liver toxicity.
Answer: B
Rationale: Dextromethorphan acts as a weak serotonin reuptake inhibitor. Concurrent use with
SSRIs, which also increase synaptic serotonin, significantly elevates the risk of serotonin
syndrome, a potentially life-threatening condition.
CORRECT ANSWER : B
Primary Care Provider, 5th Edition] EXAM with
Questions and Answers/Plus a Rationale Updated
2026 A+/Instant Download PDF
EXAM COVERAGE
1. Principles of Pharmacokinetics and Pharmacodynamics
2. Pharmacology of the Autonomic Nervous System
3. Cardiovascular and Antihypertensive Agents
4. Respiratory System Pharmacology
5. Endocrine and Metabolic Agents
6. Gastrointestinal and Renal Pharmacology
7. Psychopharmacology and Neurological Agents
8. Anti-infective and Antimicrobial Therapy
9. Pain Management and Analgesics
10. Evidence-Based Prescribing and Clinical Decision Making
1. A 68-year-old patient with chronic heart failure and renal insufficiency presents for a medication
review. The patient is currently taking lisinopril, furosemide, and spironolactone. Laboratory
results show a serum potassium of 5.6 mEq/L and a creatinine clearance of 35 mL/min. Which
action is the most appropriate management strategy?
A. Continue all medications as prescribed and recheck potassium in 2 weeks.
, B. Discontinue the spironolactone and monitor potassium levels closely.
C. Increase the dose of lisinopril to improve cardiac output.
D. Switch the patient to a thiazide diuretic for better potassium balance.
Answer: B
Rationale: Spironolactone is a potassium-sparing diuretic that carries a high risk of
hyperkalemia, particularly in patients with renal impairment or those taking ACE inhibitors like
lisinopril. Discontinuing the spironolactone is the safest immediate action to address the
hyperkalemia (5.6 mEq/L). Increasing lisinopril or switching to another diuretic does not resolve
the current electrolyte toxicity.
CORRECT ANSWER : B
2. A patient with type 2 diabetes and stable coronary artery disease is being evaluated for glycemic
control. The patient has a history of heart failure with reduced ejection fraction. Which class of
antidiabetic agents should be prioritized for this patient due to its proven cardiovascular
mortality benefits?
A. Sulfonylureas (e.g., glipizide)
B. Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin)
C. Sodium-glucose cotransporter-2 (SGLT2) inhibitors (e.g., empagliflozin)
D. Thiazolidinediones (e.g., pioglitazone)
Answer: C
Rationale: SGLT2 inhibitors have established clinical evidence for reducing cardiovascular
death and hospitalizations in patients with heart failure and T2DM. DPP-4 inhibitors are neutral
regarding heart failure, sulfonylureas have a risk of hypoglycemia, and thiazolidinediones are
generally contraindicated in heart failure due to fluid retention.
CORRECT ANSWER : C
3. A 45-year-old female presents with primary hypothyroidism. She is currently stable on 112 mcg
of levothyroxine daily. She is now requesting a prescription for a combined oral contraceptive.
What is the most important clinical consideration when starting this therapy?
A. The estrogen in the contraceptive increases thyroid-binding globulin, requiring a potential
increase in levothyroxine dose.
B. The contraceptive will decrease the absorption of levothyroxine in the gut.
, C. The contraceptive must be taken at least 6 hours apart from the thyroid medication.
D. The patient will likely require a switch to liothyronine (T3) for stability.
Answer: A
Rationale: Estrogen increases the levels of thyroid-binding globulin, which binds to thyroid
hormone and reduces the amount of free hormone available, necessitating a dose increase of
levothyroxine. Absorption interference (Option B) is not the primary mechanism, and T3 (Option
D) is not indicated for stability.
CORRECT ANSWER : A
4. A patient has been prescribed a non-selective beta-blocker for migraine prophylaxis. During the
assessment, the patient mentions a history of asthma. Which clinical concern is most urgent?
A. The beta-blocker may cause excessive bradycardia in asthma patients.
B. Non-selective beta-blockers can cause bronchoconstriction by blocking beta-2 receptors in the
lungs.
C. The patient will experience a significant increase in their albuterol requirements.
D. Asthma medications will render the beta-blocker completely ineffective.
Answer: B
Rationale: Non-selective beta-blockers antagonize both beta-1 (cardiac) and beta-2 (bronchial)
receptors, which can precipitate bronchospasm in patients with reactive airway disease. This is
a classic pharmacological contraindication that necessitates caution or selection of a
cardioselective beta-1 antagonist.
CORRECT ANSWER : B
5. A patient with severe seasonal allergies is taking fexofenadine but reports inadequate control of
nasal congestion. Which pharmacological intervention is the best evidence-based step?
A. Add an oral pseudoephedrine for long-term use.
B. Transition the patient to an intranasal corticosteroid (e.g., fluticasone).
C. Increase the dose of fexofenadine to twice the standard daily dose.
D. Add a first-generation antihistamine like diphenhydramine to the regimen.
Answer: B
, Rationale: Intranasal corticosteroids are the most effective monotherapy for allergic rhinitis,
particularly for congestion. Pseudoephedrine has cardiovascular risks with long-term use,
higher antihistamine doses offer little additional benefit for congestion, and first-generation
antihistamines cause sedation.
CORRECT ANSWER : B
6. A patient is taking warfarin for atrial fibrillation. The patient is diagnosed with a urinary tract
infection and is prescribed sulfamethoxazole-trimethoprim (Bactrim). What is the primary drug-
drug interaction mechanism?
A. Bactrim increases the metabolism of warfarin, decreasing its effect.
B. Bactrim inhibits CYP2C9, significantly increasing the INR and bleeding risk.
C. The patient will experience a synergistic decrease in blood pressure.
D. Bactrim binds to warfarin in the GI tract, preventing absorption.
Answer: B
Rationale: Sulfamethoxazole-trimethoprim is a potent inhibitor of CYP2C9, the enzyme
responsible for the metabolism of the S-enantiomer of warfarin. This interaction dramatically
increases warfarin levels and bleeding risk, requiring preemptive dose reductions or close
monitoring.
CORRECT ANSWER : B
7. A patient with stable depression is treated with fluoxetine (SSRI). The patient requests a
prescription for dextromethorphan for a cough. What is the potential risk of this combination?
A. Reduced antitussive effect.
B. Serotonin syndrome.
C. Potentiation of sedation.
D. Acute liver toxicity.
Answer: B
Rationale: Dextromethorphan acts as a weak serotonin reuptake inhibitor. Concurrent use with
SSRIs, which also increase synaptic serotonin, significantly elevates the risk of serotonin
syndrome, a potentially life-threatening condition.
CORRECT ANSWER : B
